The National Medical Journal of India

SELECTED SUMMARY
Year
: 2021  |  Volume : 34  |  Issue : 2  |  Page : 90--91

Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?


Ajay Gogia1, Abhenil Mittal1, Atul Sharma1, Hari Krishna Raju Sagiraju2 
1 Department of Medical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India
2 Department of Preventive Oncology, National Cancer Institute, All India Institute of Medical Sciences, Jhajjar, Haryana, India

Correspondence Address:
Atul Sharma
Department of Medical Oncology, Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi
India




How to cite this article:
Gogia A, Mittal A, Sharma A, Sagiraju HK. Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?.Natl Med J India 2021;34:90-91


How to cite this URL:
Gogia A, Mittal A, Sharma A, Sagiraju HK. Short-duration adjuvant trastuzumab therapy in human epidermal growth factor receptor 2-positive breast cancers: Has its time come?. Natl Med J India [serial online] 2021 [cited 2021 Oct 18 ];34:90-91
Available from: http://www.nmji.in/article.asp?issn=0970-258X;year=2021;volume=34;issue=2;spage=90;epage=91;aulast=Gogia;type=0